The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
Doxorubicin combined with pembrolizumab has shown promise in the treatment of patients with advanced anthracycline-naïve sarcoma, according to phase 1/2 study findings.
In a large clinical study, which of the following agents yielded durable responses in patients with epithelioid sarcoma?
True or False: Cabozantinib has shown anti-tumor activity in patients with advanced Ewing sarcoma and osteosarcoma.
A maintenance therapy regimen comprising oral cyclophosphamide plus celecoxib has demonstrated feasibility in patients with metastatic Ewing sarcoma.
In a phase 2 study of patients with advanced epithelioid sarcoma, tazemetostat demonstrated durable clinical response and favorable safety.
The FDA has approved pomalidomide for use in adults with AIDS-related Kaposi sarcoma unresponsive to antiretroviral therapy and Kaposi sarcoma in HIV-negative adults.
Germline genetic testing may be warranted for patients with osteosarcoma, according to findings from a study by Lisa Mirabello, PhD, et al.